The MSKCC SPORE in Prostate Cancer represents an innovative and comprehensive approach to the disease. We have developed a multidisciplinary and multiinstitutional program of clinical and laboratory research focused on the development of better strategies to diagnose, treat and prevent prostate cancer (CaP). Major strengths of the program at MSKCC include our access to patients at all stages of the disease and a track record of multimodal approaches (surgery, radiation oncology and medical oncology) in the treatment of CaP. In addition, we have designed a new resource, the Prostate Cancer Detection Center, to identify patients at high risk for the disease. With these patient resources we can evaluate chemopreventive strategies, unique and innovative approaches to improved detection and staging, and developing more effective strategies for the treatment of clinically localized, as well as, metastatic disease. The SPORE has 7 projects that address (i) predictors of response to therapy (ii) monoclonal antibody characterization (iii) genetic epidemiology (iv) quality of life interventions (v) developmental cytokine immunotherapy (vi) growth factor mechanisms and (vii) chemoprevention models. These projects are supported by 4 Cores: Administrative, Clinical, Biostatistics and Pathology. In addition, we have created the mechanism for Developmental Research Programs and Career Development and have selected some projects and candidates in these areas. We believe that the MSKCC SPORE in Prostate Cancer is a program focused on the translation of new biological information into the clinic and in collaboration with other SPORE's as well positioned to make an impact on new approaches to cure and prevent prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory Grants (P20)
Project #
1P20CA058192-01
Application #
3100576
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1992-09-30
Project End
1995-09-29
Budget Start
1992-09-30
Budget End
1993-09-29
Support Year
1
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Vieweg, J; Boczkowski, D; Roberson, K M et al. (1995) Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res 55:2366-72
Wang, Y; Corr, J G; Thaler, H T et al. (1995) Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst 87:1456-62
Israeli, R S; Miller Jr, W H; Su, S L et al. (1995) Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction. J Urol 153:573-7
Vieweg, J; Heston, W D; Gilboa, E et al. (1994) An experimental model simulating local recurrence and pelvic lymph node metastasis following orthotopic induction of prostate cancer. Prostate 24:291-8
Saito, S; Bannerji, R; Gansbacher, B et al. (1994) Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res 54:3516-20
Cohen, D W; Simak, R; Fair, W R et al. (1994) Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues. J Urol 152:2120-4
Israeli, R S; Powell, C T; Corr, J G et al. (1994) Expression of the prostate-specific membrane antigen. Cancer Res 54:1807-11
Israeli, R S; Miller Jr, W H; Su, S L et al. (1994) Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res 54:6306-10
Begg, C B (1994) Methodological issues in studies of the treatment, diagnosis, and etiology of prostate cancer. Semin Oncol 21:569-79